Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

Figures & data

Table 1. Patient and treatment characteristics.

Characteristic	Total cohort
Total patients, number	38
Female sex, number (%)	14 (36.8)
Age at transplantation, median (range)	60 (20–73)
Donor age, median (range)	42 (20–71)
HCT-CI score, median (range)	4 (0–10)
Prior allogeneic transplantation, number (%)	11 (28.9)
Sex mismatch of male recipient / female donor, number (%)	3 (7.9)
Diagnosis, number (%)
AML	20 (52.6)
MDS	8 (21.1)
PMF	2 (5.3)
CML	1 (2.6)
CMML	1 (2.6)
MM	2 (5.3)
ALL	1 (2.6)
NHL	2 (5.3)
Sezary Syndrome	1 (2.6)
Disease status at transplantation, number (% of 20 patients with AML)
Remission	15 (75.0)
Active	4 (20.0)
MRD positive	1 (5.0)
Conditioning regimen, number (%)
Fludarabine + Melphalan (100 mg/m^2)	2 (5.3)
Fludarabine + Melphalan (140 mg/m^2)	34 (89.5)
Fludarabine + Melphalan (140 mg/m^2) + ATG	2 (5.3)
ABO status, number (% of 37 patients with data available)
Major mismatch	7 (18.9)
Minor mismatch	13 (35.1)
Full match	17 (45.9)
CMV serostatus, number (%, of 37 patients with data available)
Donor positive / Recipient positive	14 (37.8)
Donor negative / Recipient positive	7 (18.9)
Donor negative / Recipient negative	14 (37.8)
Donor positive / Recipient negative	2 (5.4)

Figure 1. (A–B) Kaplan-Meier survival estimates showing overall survival and disease-free survival, respectively, after transplantation for the whole cohort. (C–D) Cumulative incidences of relapse and NRM after transplantation for the whole cohort. Gray shaded areas indicate 95% confidence intervals.